menu
    • menu
    [{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MRTX1133","moa":"KRASG12D selective","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for MRTX1133

    Menu

    MRTX1133

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mirati Therapeutics

                            U.S.A arrow
                            Spring Meeting
                            Not Confirmed

                            Mirati Therapeutics

                            U.S.A arrow
                            Spring Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MRTX1133

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Select...

                            Details : MRTX1133 is an investigational, highly potent, selective and reversible inhibitor of KRASG12D that is optimized to sustain near complete target inhibition. It is currently being investigated for KRASG12D-driven cancers.

                            Product Name : MRTX1133

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 19, 2023

                            Lead Product(s) : MRTX1133

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth